Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189

NCT01310881 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Neuralstem Inc.